CTFH and Insilico Collaborate on Accelerating First-in-class Therapeutics Using AI
Research Collaboration Highlights
- The collaboration aims to accelerate drug discovery and development with an AI-enabled platform for triple-negative breast cancer;
- CTFH is one of the top pharmaceutical companies in China focused on innovative drug discovery and development, with a strong internal R&D team and integrated R&D capabilities;
- The project value is up to $200 million, including an upfront payment, milestone payments, and royalties based on the net product sales;
- CTFH has achieved significant milestones in first-in-class drug development. With this partnership, CTFH will generate novel molecules with specified properties using Insilico's next-generation AI platform;
- This partnership will speed up the R&D process, reduce the cost and ultimately benefit the patients;
HONG KONG, and NANJING, CHINA - October 9, 2019 (12PM London time) - Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program research collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. ("CTFH"), taking on previously undruggable targets. Insilico Medicine will be eligible to receive up to $200 million for the achievement of milestone payments and royalties based on the net sales on the products from the collaboration. This partnership is expected to accelerate drug discovery and development with an AI-enabled platform for triple-negative breast cancer.
CTFH is an active adopter of state-of-the-art technologies and has achieved significant milestones in first-in-class drug development. Wenyu Xia, General Manager of CTFH, said: "We are very pleased to establish the partnership with Insilico Medicine, entering the new era of AI-enabled drug development. We look forward to a long-term partnership with Insilico Medicine. As the premier AI drug discovery company in the industry, Insilico Medicine has demonstrated capabilities to generate novel molecules with specified properties using its next-generation AI platform. We believe that this collaboration will speed up the R&D process, reduce the cost and provide greater benefits to patients."
Last month, Insilico Medicine published a landmark paper in Nature Biotechnology, demonstrating the application of its generative tensorial reinforcement learning systems in the generation of novel molecules for simple kinases in 46 days, including experimental validation. It also announced a $37 million round led by prominent biotechnology and AI investors.
MORE IN ITECHPOST
What Is M2M & IoT?
While IoT and M2M technologies do have some elements in common, they are, in fact, two distinct concepts. M2M applications differ from what IoT is intended for and mostly cover the industrial field. IoT connected objects, on the other hand, pertain more to everyday life and apply to the general public.
Wellness Technology is a Billion Dollar Industry. Here Comes the Next Wave: Death Positive & Grief Wellness
The World Health Organization estimates that 25% of all people will be affected by mental or neurological disorders at some point in their lives, with roughly 450 million individuals currently struggling with a condition.
Find the build that’s right for you in the Metamorph League and experiment with other playstyles.
Defeat bosses in the Metamorph League and get tons of PoE currency like PoE orbs by knowing what the right build for you is in our Metamorph build guide!
Design Trends you Should Know
For everything from product labels to websites, the right design has a huge impact on people. Keeping up with the latest design styles is important because it lets organizations present a trendier and more modern vibe to their audience. Here are some of the biggest trends you can expect to see in the upcoming years.